Valneva SE and Serum Institute of India (SII) announced that they have mutually agreed to discontinue their licence agreement for Valneva’s single-shot chikungunya vaccine.

Valneva´s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialisation for endemic high-risk countries, thereby accelerating access for regions most affected by the disease.

Supporting access to the vaccine in Low-and-Middle-Income Countries (LMICs) falls within the framework of the funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union.